Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studies

Docetaxel immunonanocarriers as targeted delivery systems for HER2-positive tumor cells: preparation, characterization, and cytotoxicity studies

Mona Noori Koopaei1, Rassoul Dinarvand1,2, Mohsen Amini3, Hojatollah Rabbani4, Shaghayegh Emami4, Seyed Nasser Ostad5, Fatemeh Atyabi1,21Novel Drug Delivery Laboratory, Faculty of Pharmacy, 2Nanotechnology Research Center, 3Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of...

Full description

Bibliographic Details
Main Authors:	Noori Koopaei M, Dinarv, R, Amini M, Rabbani H, Emami S, Ostad SN, Atyabi F
Format:	Article
Language:	English
Published:	Dove Medical Press 2011-09-01
Series:	International Journal of Nanomedicine
Online Access:	http://www.dovepress.com/docetaxel-immunonanocarriers-as-targeted-delivery-systems-for-her2-pos-a8243

Similar Items

Chitosan&ndash;Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study
by: Ostad SN, et al.
Published: (2012-04-01)

Enhanced Oral Delivery of Docetaxel Using Thiolated Chitosan Nanoparticles: Preparation, In Vitro and In Vivo Studies
by: Shahrooz Saremi, et al.
Published: (2013-01-01)

Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab
by: Yousefpour P, et al.
Published: (2011-09-01)

Mesoporous silica nanoparticles functionalized with folic acid/methionine for active targeted delivery of docetaxel
by: Khosravian P, et al.
Published: (2016-12-01)

Increased paclitaxel cytotoxicity against cancer cell lines using a novel functionalized carbon nanotube
by: Sobhani Z, et al.
Published: (2011-04-01)

Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents
by: Rouhani H, et al.
Published: (2011-04-01)

Thiolated chitosan nanoparticles for enhancing oral absorption of docetaxel: preparation, in vitro and ex vivo evaluation
by: Shahrooz Saremi, et al.
Published: (2011-01-01)

Nanoparticles of Conjugated Methotrexate-Human Serum Albumin: Preparation and Cytotoxicity Evaluations
by: Azade Taheri, et al.
Published: (2011-01-01)

Thiolated chitosan nanoparticles as a delivery system for antisense therapy: evaluation against EGFR in T47D breast cancer cells
by: Talaei F, et al.
Published: (2011-09-01)

Formulation and evaluation of docetaxel nanosuspensions: In-vitro evaluation and cytotoxicity
by: Mohamed A. Ibrahim, et al.
Published: (2019-01-01)

Inclusion Complex of Docetaxel with Sulfobutyl Ether β-Cyclodextrin: Preparation, In Vitro Cytotoxicity and In Vivo Safety
by: Lili Ren, et al.
Published: (2020-10-01)

The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells
by: Reem T. Attia, et al.
Published: (2016-06-01)

Mesenchymal stem cell exosomes: a two-edged sword in cancer therapy
by: Vakhshiteh F, et al.
Published: (2019-04-01)

Evaluation of a self-nanoemulsifying docetaxel delivery system
by: S. Akhtartavan, et al.
Published: (2019-01-01)

Targeted delivery of doxorubicin to HER2 positive tumor models
by: Gomari H, et al.
Published: (2019-07-01)

Preparation and Characterization of Self-Emulsified Docetaxel
by: Gyeong Hae Kim, et al.
Published: (2011-01-01)

Formulation of docetaxel using prodrugs for intravenous delivery
by: Chang-Gu Keum, et al.
Published: (2012-01-01)

Polyanionic carbohydrate doxorubicin&ndash;dextran nanocomplex as a delivery system for anticancer drugs: in vitro analysis and evaluations
by: Yousefpour P, et al.
Published: (2011-07-01)

In vitro evaluation of mutagenicity and cytotoxicity of four root canal sealers
by: Zarrabian M., et al.
Published: (2007-07-01)

Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel
by: Ashley M. Hopkins, et al.
Published: (2019-08-01)

Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer
by: Andrea Rocca, et al.
Published: (2021-02-01)

Targeted Delivery Of Doxorubicin To HER2 Positive Tumor Models [Corrigendum]
by: Gomari H, et al.
Published: (2019-09-01)

Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison
by: Sapino Anna, et al.
Published: (2010-02-01)

Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive <it>Breast</it> Cancer Cells <it>in Vitro</it>
by: Liu Zhe, et al.
Published: (2012-07-01)

Cytotoxic effect of a dentin bonding agent: AdheSE
by: Banava S., et al.
Published: (2007-05-01)

Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells
by: Irin Tanaudommongkon, et al.
Published: (2020-07-01)

Effect of surface ligand density on cytotoxicity and pharmacokinetic profile of docetaxel loaded liposomes
by: Chun Chu, et al.
Published: (2016-10-01)

Targeted Co-Delivery of Docetaxel and cMET siRNA for Treatment of Mucin1 Overexpressing Breast Cancer Cells
by: Naime Majidi Zolbanin, et al.
Published: (2018-08-01)

Lipid based nanocarriers for chemotherapeutic drug docetaxel and vaccine delivery
by: Yanasarn, Nijaporn
Published: (2011)

Advances in Nanocarriers for Effective Delivery of Docetaxel in the Treatment of Lung Cancer: An Overview
by: S. Aishah A. Razak, et al.
Published: (2021-01-01)

A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells
by: Shen Y, et al.
Published: (2019-05-01)

Preparation and characterization of self-assembled nanoparticles based on low-molecular-weight heparin and stearylamine conjugates for controlled delivery of docetaxel
by: Kim DH, et al.
Published: (2014-12-01)

Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of Survivin in lung cancer cells
by: Li Hui, et al.
Published: (2011-03-01)

Cytotoxic effects of Clusterin antisense oligonucleotides and Docetaxel on two prostate cancer cell lines
by: N. Bakhtiari, et al.
Published: (2015-06-01)

Cytotoxicity of Two Species of Glaucium from Iran
by: F Hadjiakhoondi, et al.
Published: (2013-02-01)

Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends
by: Sohail MF, et al.
Published: (2018-06-01)

Docetaxel delivery using folate-targeted liposomes: in vitro and in vivo studies
by: Roghayyeh Vakili-Ghartavol, et al.
Published: (2020-04-01)

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
by: Shengnan Yu, et al.
Published: (2019-08-01)

Enhanced Cytotoxic Activity of Docetaxel-Loaded Silk Fibroin Nanoparticles against Breast Cancer Cells
by: Ahmed Al Saqr, et al.
Published: (2021-04-01)

Cytotoxicity assay of fenugreek aqueous extract on NIH3T3 fibroblast cells
by: Ostad SN, et al.
Published: (2008-11-01)